Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yuanbo Lan"'
Autor:
Quanxian Liu, Lu Huang, Hong Yan, Zhaojing Zong, Zhenyong Chen, Xiaoyan Wu, Ling Chen, Yuanbo Lan
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveTo analyze the clinical and laboratory characteristics and to identify predictors of moderate to severe anti-tuberculosis drug-induced liver injury (ATB-DILI) in patients with tuberculosis.MethodsThis prospective study enrolled Tuberculosis
Externí odkaz:
https://doaj.org/article/11d585c538194eaa9e68c44dc708f28f
Autor:
Fan Zou, Zhiwei Cui, Siyu Lou, Yingyong Ou, Chengyu Zhu, Chengjie Shu, Junyou Chen, Ruizhen Zhao, Zhu Wu, Li Wang, Zhenyong Chen, Huayu Chen, Yuanbo Lan
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Linezolid is an oxazolidinone antibiotic that is active against drug-resistant Gram-positive bacteria and multidrug-resistant Mycobacterium tuberculosis. Real-world studies on the safety of linezolid in large populations are lacking. Th
Externí odkaz:
https://doaj.org/article/3381342df8ee457a9ac2d16a17da312b
Autor:
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps. The information about its adverse drug reactions is mainly derived from clinical t
Externí odkaz:
https://doaj.org/article/1cd6d2a55aa4477096c2ef86d950290f
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
BackgroundAs one of the top three high tuberculosis (TB) burden countries, China is a country where the overall TB incidence continues to decline. However, due to its large population and area, the increased TB burden exists in regional areas.Methods
Externí odkaz:
https://doaj.org/article/eebfc7b8f3a04a729395c61f6ed6d158
Autor:
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan
Publikováno v:
Frontiers in Pharmacology; 2024, p1-14, 14p
Autor:
Shun Lu, Jianying Zhou, Hong Jian, Lin Wu, Ying Cheng, Yun Fan, Jian Fang, Gongyan Chen, Zhihong Zhang, Dongqing Lv, Liyan Jiang, Rong Wu, Xiangming Jin, Xiaodong Zhang, Junhong Zhang, Conghua Xie, Gengyun Sun, Dongning Huang, Jiuwei Cui, Renhua Guo, Zhigang Han, Zhendong Chen, Jin Liang, Wu Zhuang, Xingsheng Hu, Aimin Zang, Yi Zhang, Shundong Cang, Yuanbo Lan, Xi Chen, Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang Wu
Publikováno v:
The Lancet Respiratory Medicine.
Publikováno v:
Journal of Infection in Developing Countries. Mar2019, Vol. 13 Issue 3, p261-264. 4p.
Publikováno v:
Journal of Infection in Developing Countries. Sep2023, Vol. 17 Issue 9, p1351-1355. 5p.
Autor:
Zhimin, Cao, Yuanbo, Lan, Ling, Chen, Min, Xiang, Zhiyuan, Peng, Jianyong, Zhang, Hong, Zhang
Publikováno v:
Infection and Drug Resistance
Background China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB), and pyrazinamide is one of the anti-TB drugs used for the shorter MDR-TB treatment regimen. The aim of this study was to determine the correlation bet